{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:58:54Z","timestamp":1791892734783,"version":"4.3.4"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":15223,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1974,5]]},"abstract":"<jats:p>Three groups were investigated to determine whether methemoglobin formation is greater than normal in chronic phenacetin analgesic abusers. Group I (8 patients) was comprised of nonabusers with normal renal function; Group II (12 patients), of nonabusers with impaired renal function; Group III (9 patients), of abusers who had consumed phenacetin in combination with acetylsalicylic acid, caffeine, and codeine for 7 to 20 years, and had Similarly impaired renal function. Each subject was given 2 gm of phenacetin in a single dose, orally. Analysis of variance revealed significantly higher methemoglobin levels in Group III than in Groups I and II (p &lt; 0.005). After cessation of analgesic abuse, there was a reduction in methemoglobin formation in 5 of 6 Group III patients. Continued heavy consumption of phenacetin may lead to increased production of the toxic metabolites that lead to methemoglobin formation.<\/jats:p>","DOI":"10.1002\/cpt1974155521","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:28:16Z","timestamp":1451957296000},"page":"521-527","source":"Crossref","is-referenced-by-count":14,"title":["Methemoglobin formation in analgesic nephropathy"],"prefix":"10.1111","volume":"15","author":[{"given":"M. H.","family":"Gault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. T.","family":"Shahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1974155521","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1974155521","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1974155521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:32:37Z","timestamp":1699363957000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1974155521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1974,5]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1974,5]]}},"alternative-id":["10.1002\/cpt1974155521"],"URL":"https:\/\/doi.org\/10.1002\/cpt1974155521","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1974,5]]}}}